We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

10 hedge funds and large institutions have $3.66M invested in Seelos Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more capital invested

Capital invested by funds: $1.1M → $3.66M (+$2.56M)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

43% more funds holding

Funds holding: 7 → 10 (+3)

Holders
10
Holders Change
+3
Holders Change %
+42.86%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.97M
2
BlackRock
BlackRock
New York
+$1.12M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$485K
4
Millennium Management
Millennium Management
New York
+$259K
5
Jane Street
Jane Street
New York
+$210K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$883K
2
Citadel Advisors
Citadel Advisors
Florida
-$24K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$7K
4
California Public Employees Retirement System
California Public Employees Retirement System
California
-$5K
5
FWM
Frontier Wealth Management
Missouri
-$4K

SEEL Hedge Fund Activity: Q1 2019 in Review

10 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2019, worth a combined $3.66M — up 233% from $1.1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SEEL positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.97M. The largest seller was Armistice Capital, exiting entirely with an estimated $883K sold.

  • 10 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2019, up from 7 in Q4 2018.
  • Funds reported $3.66M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2019, up 233% quarter-over-quarter.
  • 5 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2019 and 2 closed out, a net change of +3 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2019 was Renaissance Technologies, an estimated $1.97M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2019 was Armistice Capital, an estimated $883K sold.

Based on aggregated 13F filings for Q1 2019.